Search results for "pemphigus"

showing 10 items of 29 documents

Mycophenolate is effective in the treatment of pemphigus vulgaris.

1999

Background Pemphigus vulgaris is a potentially life-threatening autoimmune disease. Although combination therapies with prednisone and azathioprine are usually effective in controlling the disease, some patients either do not respond to this treatment or show early relapses. Objective To find out whether mycophenolate mofetil would be an effective drug in controlling pemphigus vulgaris in patients who failed initial treatment with azathioprine and prednisone. Results Twelve patients who were initially diagnosed as having pemphigus vulgaris and had relapsed while undergoing treatment with azathioprine (1.5-2 mg/kg of body weight) and prednisolone (2 mg/kg of body weight) subsequently receive…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentPrednisoloneAzathioprineDermatologyMycophenolic acidPrednisoneAzathioprineMedicineHumansChemotherapybusiness.industryPemphigus vulgarisGeneral MedicineMiddle AgedMycophenolic Acidmedicine.diseaseDermatologyPemphigusTreatment OutcomeChemotherapy AdjuvantPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsPemphigusmedicine.drugArchives of dermatology
researchProduct

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

2011

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune…

AdultNephrologyrituximab; autoimmune diseasesmedicine.medical_specialtyHealth StatusImmunologyDrug ResistanceAutoimmune DiseasesDrug HypersensitivityAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineRheumatologyimmune system diseaseshemic and lymphatic diseasesGermanyInternal medicinemedicineHumansImmunology and Allergyddc:610RegistriesRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseasebusiness.industryRetrospective cohort studymedicine.diseaseRheumatology3. Good healthLymphomaPemphigusTreatment OutcomePatient SatisfactionAntirheumatic AgentsRheumatoid arthritisImmunologyRituximabRituximabbusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleFollow-Up Studiesmedicine.drugArthritis Research & Therapy
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Effects of metformin on autoimmune immunoglobins and interferon-γ in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial.

2021

The management of pemphigus vulgaris (PV) is challenging. This study aimed to evaluate the immunomodulating effects of metformin on PV. The study was conducted in two phases: in the first phase, patients received routine first-line treatment (prednisolone plus azathioprine) for 2 months, then in the second phase, metformin was added to this regimen for another 2 months. After addition of metformin to the first-line medications, significant reductions were seen in serum IgG1 (reduced from 534.92 ± 134.83 mg/dL to 481.58 ± 130.46 mg/dL, P < 0.001), IgG4 (51.83 ± 27.26 mg/dL to 44.50 ± 26.05 mg/dL, P < 0.001) and interferon-γ (277.99 ± 108.71 pg/mL to 45.05 ± 17.080 pg/mL, P = 0.03) concentrat…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineDermatologyGastroenterologySubclassSteroidInterferon-gammaInternal medicinemedicineHumansProspective Studiesbusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseMetforminMetforminClinical trialRegimenImmunoglobulin GPrednisoloneFemalebusinessPemphigusmedicine.drugClinical and experimental dermatologyReferences
researchProduct

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.

2010

BACKGROUND: One of the major goals of pemphigus therapy is to reduce the patient's cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. OBSERVATIONS: Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

AdultMaleAdministration OralMiddle AgedMycophenolic AcidTreatment OutcomeSettore MED/35 - Malattie Cutanee E VenereeEnteric-coated Mycophenolate SodiumHumansPrednisoneDrug Therapy CombinationFemaleTablets Enteric-CoatedGlucocorticoidsImmunosuppressive AgentsPemphigusFollow-Up StudiesInternational journal of dermatology
researchProduct

Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy

1992

Five patients with severe pemphigus vulgaris refractory to conventional therapy with azathioprine and corticosteroids were treated with cyclophosphamide, vincristine and prednisone. One patient was not evaluable, while the remaining four patients showed a complete response. Duration of response was in the range of 13-94 months. Toxicity was mainly represented by alopecia, myelosuppression and gastrointestinal side-effects such as nausea/vomiting. Although cyclophosphamide and vincristine may induce severe side-effects, this association may be useful in controlling severe disease resistant to previous conventional therapies.

0301 basic medicineMalemedicine.medical_specialtyVincristineCyclophosphamideAdolescentNausea030106 microbiologyAzathioprinemacromolecular substancesGastroenterology03 medical and health sciences0302 clinical medicineRefractoryPrednisoneInternal medicinemedicineHumansPharmacology (medical)CyclophosphamideAgedPharmacologybusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseInfectious DiseasesOncologyVincristine030220 oncology & carcinogenesisVomitingPrednisoneDrug Therapy CombinationFemalemedicine.symptombusinessPemphigusmedicine.drug
researchProduct

Systematic mapping review of interventions to prevent blood loss, infection and relapse in orthognathic surgery

2023

This systematic mapping review aims to identify, describe, and organize the currently available evidence in systematic reviews (SR) and primary studies regarding orthognathic surgery (OS) co-interventions and surgical modalities, focusing on the outcomes blood loss, infection and relapse. A comprehensive search strategy was performed to identify all SRs, randomized controlled trials and observational studies that evaluate surgical modalities and perioperative co-interventions in OS that evaluate the outcomes blood loss, infection and relapse, regardless of language or publication date. Searches were conducted in MEDLINE, EMBASE, Epistemonikos, Lilacs, Web of Science, and CENTRAL. In additio…

head and neckpemphigoidlichen planusOtorhinolaryngologypemphigusSurgeryGeneral Dentistryoral lesionlupus erythematosusUNESCO:CIENCIAS MÉDICASmucocutaneous diseasesMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Diagnostic pathways and clinical significance of desquamative gingivitis:a review

2008

The term desquamative gingivitis (DG) refers to a clinical manifestation that can be caused by several disorders. Many of them are immunologically mediated; in addition to the oral cavity, they can affect extraoral mucocutaneous sites, e.g., larynx, conjunctiva, esophagus, nasal and genital mucosa, and the skin. The degree of oral, periodontal, and systemic involvement determines the overall morbidity and, sometimes, the mortality of these disorders. We comprehensively review disorders commonly associated with DG and highlight diagnostic pathways, guidelines for differential diagnosis, and oral, periodontal, and systemic implications. More rare conditions are reviewed as well. Mucous membra…

Desquamative gingivitis diagnosis erythema multiforme lichen planus pemphigoid pemphigus
researchProduct

Diagnostic Concordance between Optical Coherence Tomography and Histological Investigations for Immune-Mediated Desquamative Gingivitis: Observationa…

2021

Desquamative gingivitis (DG) denotes a heterogeneous immune-mediated disease for which early diagnosis represents a great challenge. The main aim of this study is to validate diagnostic concordance between specific Optical Coherence Tomography (OTC) patterns for DG related to oral Lichen Planus (OLP), Pemphigus Vulgaris (PV), and Mucous Membrane Pemphigoid (MMP) and definitive histological diagnosis. Forty-three patients with suspected immune-mediated DGs, were progressively recruited. Before biopsy, an OCT preliminary evaluation was performed using specific pre-determined OCT diagnostic patterns (i.e., morphology and localization of blisters, status of the basal membrane, epithelial thickn…

Pathologymedicine.medical_specialtyoptical coherencediagnosisHealth Toxicology and MutagenesisConcordancePemphigoid Benign Mucous Membraneimmune-mediated diseasestomographyArticlesymbols.namesakeOptical coherence tomographyBiopsymedicineHumansMedical diagnosisskin and connective tissue diseasesFisher's exact testmedicine.diagnostic_testintegumentary systembusiness.industryPemphigus vulgarisPublic Health Environmental and Occupational HealthRReproducibility of Resultsmedicine.diseaseGingivitiseye diseasesdesquamative gingivitisDesquamative gingivitisstomatognathic diseasessymbolsMedicineOral lichen planusbusinessTomography Optical CoherencePemphigusInternational Journal of Environmental Research and Public Health
researchProduct

Factitial pemphigus-like lesions

2007

The maxillofacial region is rarely subjected to self-inflicted conditions such as factitious disease. Nasal ulceration, facial emphysema, periorbital ecchymosis, mandibular subluxation, gingival and mucosal ulceration, dental and salivary gland pain and glossopharyngeal neuralgia have been reported as possible manifestations of factitious disease. We report a case of a young woman who presented with unilateral bullous and ulcerative oral and erythematous facial lesions that were initially diagnosed as pemphigus vulgaris but was later determined to be secondary to self-inflicted injuries. To the best of the authors? knowledge, this clinical scenario has not been previously reported in the co…

oralstomatognathic diseasespemphigus vulgarisUNESCO::CIENCIAS MÉDICASBullous:CIENCIAS MÉDICAS [UNESCO]erythematousfacialfactitious disease
researchProduct